Department of Gastroenterology, Putuo People's Hospital, Tongji University School of Medicine, Shanghai 200060, China; Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Biomed Pharmacother. 2021 Jan;133:111036. doi: 10.1016/j.biopha.2020.111036. Epub 2020 Nov 28.
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancer-related deaths globally, with few effective therapeutic options. Bile acids (BAs) are synthesized from cholesterol in the liver and can be modulated by farnesoid X receptor (FXR) and G-protein coupled BA receptor 1 (GPBAR1/TGR5). Alterations in BAs can affect hepatic metabolic homeostasis and contribute to the pathogenesis of liver cancer. Increasing evidence points to the key role of bacterial microbiota in the promotion and development of liver cancer. They are also involved in the regulation of BA synthesis and metabolism. The purpose of this review is to integrate related articles involving gut microbiota, BAs and HCC, and review how the gut microbiota-BA signaling axis can possibly influence the development of HCC.
肝细胞癌（HCC）是最常见的原发性肝脏恶性肿瘤，也是全球癌症相关死亡的主要原因，目前治疗选择有限。胆汁酸（BAs）在肝脏中由胆固醇合成，并可受法尼醇 X 受体（FXR）和 G 蛋白偶联 BA 受体 1（GPBAR1/TGR5）调节。BAs 的改变会影响肝脏的代谢稳态，并导致肝癌的发病机制。越来越多的证据表明，细菌微生物群在促进和发展肝癌中起着关键作用。它们还参与了 BA 合成和代谢的调节。本综述的目的是整合涉及肠道微生物群、BAs 和 HCC 的相关文章，并综述肠道微生物群-BA 信号轴如何可能影响 HCC 的发展。
